Accelerated stability testing of gene therapy formulations is a test performed during the development of gene therapy formulations to assess the stability of gene therapy formulations during storage and use. CD Formulation provides effective technical support and comprehensive testing solutions for accelerated stability testing of gene therapy formulations, which are often performed under more severe conditions than the actual storage conditions. The tests we offer are typically performed under more severe conditions than actual storage conditions, such as elevated temperatures to accelerate the degradation process of the formulation, to quickly obtain data on the stability of the gene therapy formulation. This service helps researchers predict the expiration date and stability of a product under normal storage conditions and provides a basis for determining the correct storage conditions and packaging.
Accelerated stability testing helps to quickly predict the long-term stability of gene therapy formulations under routine storage conditions. By testing the rate of degradation of a formulation under stressful conditions such as elevated temperature and humidity, it is possible to assess how it may deteriorate in a normal storage environment. This is critical for optimizing product formulations, selecting appropriate storage conditions, and determining product expiration dates. Specifically, this is mainly reflected in the following aspects.
First of all, we can help our clients to develop the most suitable accelerated stability test program according to the product characteristics, including the determination of the test conditions, such as temperature, humidity, and the evaluation time point and so on. In this process, we need to take into account the complex degradation pathways of gene therapy formulations, and consider various of factors to provide customers with the most scientific and reasonable measurement program.
We provide professional sample preparation and storage services to ensure that all samples are handled under standardized conditions to avoid interference with test results by external factors. We simulate the degradation that may occur during prolonged storage by storing target samples under accelerated conditions.
We use advanced analytical techniques, such as HPLC and LC-MS, to monitor the degradation of gene therapy formulations at different time points. Based on the degradation data, we perform modeling of acceleration factors and degradation rates to predict stability under routine storage conditions.
At the end of the test, combined with the analysis results, we will provide a detailed analysis report covering key data such as degradation rate, and predicted stability duration, and give suggestions on storage conditions, formulation optimization, etc., to help customers make scientific development decisions when developing gene therapy formulations.
Fig.1 Gene therapy formulation accelerated stability testing process. (CD Formulation)
Platforms & Technologies | Content Description |
---|---|
Plasmid vector analysis | Using advanced molecular biology techniques to analyze the stability of plasmid vectors, with plasmid vector stability assays we can ensure the stability of plasmid vectors in gene therapy formulations. |
Viral vector analysis | Includes adeno-associated virus vector (AAV) analysis, using various advanced techniques to detect solid and empty capsid rates. |
Genomic titer assays | Genomic titer assays play an important role in the accelerated stability testing of gene therapy formulations, and we commonly use qPCR and ddPCR to test the titer of viral vector-based products. |
rcAAV residue detection | Detection using AAV samples infected with sensitive cells combined with qPCR analysis. |
Whole genome sequencing | Uses next-generation sequencing technology to provide comprehensive genetic stability test results. |
Bioinformatics analysis | Data analysis using bioinformatics tools in conjunction with whole genome sequencing results. |
Technology: Accelerated stability testing
Journal: AAPS PharmSciTech
IF: 3.3
Published: 2021
In pharmaceutical development, long-term stability testing is essential to ensure product stability, as issues discovered later can lead to costly re-formulations and delays. Predicting stability early in development is challenging, but the Accelerated Stability Assessment Program (ASAP), which uses a modified Arrhenius equation and isoconversion method, offers a quicker alternative for evaluating product stability and shelf-life. Although most studies focus on small drug molecules, this study applied ASAP to ascorbic acid (AA) and a cyclic hexapeptide (cFEE). The results, based on degradation products, showed that ASAP accurately predicted stability, validating its usefulness for long-term stability assessment.
Fig.2 Application of accelerated predictive stability studies to formulations for shelf-life assessment. (Legrand P, et al. 2021)
Accelerated stability testing is an indispensable part of the gene therapy formulation development process, which plays a crucial role in ensuring the safety, efficacy and quality control of the product. CD Formulation, as a professional gene therapy formulation development company, aims to provide comprehensive solutions for gene therapy formulation development. If you are interested in us, please feel free to contact us.
References